Search

Your search keyword '"Delforge, Michel"' showing total 15 results
Start Over Author "Delforge, Michel" Journal leukemia & lymphoma
15 results on '"Delforge, Michel"'

1. An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

Author

Rodríguez Otero, Paula, primary, Towle, Kevin, additional, Cope, Shannon, additional, Caisip, Clyde, additional, Davies, Faith E., additional, Delforge, Michel, additional, Weisel, Katja, additional, Marshall, Thomas S., additional, Karampampa, Korinna, additional, Ayers, Dieter, additional, Mojebi, Ali, additional, Braverman, Julia, additional, Farrell, James, additional, and Dhanda, Devender, additional

Published
2023
Full Text
View/download PDF

2. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma

Author

Rodriguez-Otero, Paula, primary, Ayers, Dieter, additional, Cope, Shannon, additional, Davies, Faith E., additional, Delforge, Michel, additional, Mojebi, Ali, additional, Jansen, Jeroen P., additional, Weisel, Katja, additional, Hege, Kristen, additional, and Dhanasiri, Sujith, additional

Published
2021
Full Text
View/download PDF

3. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Author

Goldman-Mazur, Sarah, primary, Jurczyszyn, Artur, additional, Castillo, Jorge J., additional, Waszczuk-Gajda, Anna, additional, Grząśko, Norbert, additional, Radocha, Jakub, additional, Bittrich, Max, additional, Kortüm, Klaus Martin, additional, Gozzetti, Alessandro, additional, Usnarska-Zubkiewicz, Lidia, additional, Valls, Julio D., additional, Jayabalan, David S., additional, Niesvizky, Ruben, additional, Kelman, Julia, additional, Coriu, Daniel, additional, Rosiñol, Laura, additional, Szukalski, Łukasz, additional, González-Calle, Veronica, additional, Mateos, María-Victoria, additional, Jamroziak, Krzysztof, additional, Hus, Iwona, additional, Avivi, Irit, additional, Cohen, Yael, additional, Mazur, Piotr, additional, Suska, Anna, additional, Chappell, Aimee, additional, Madduri, Deepu, additional, Chhabra, Saurabh, additional, Kleman, Ariel, additional, Hari, Parameswaran, additional, Delforge, Michel, additional, Robak, Paweł, additional, Gentile, Massimo, additional, Kozłowska, Izabela, additional, Goldberg, Stuart L., additional, Czepiel, Jacek, additional, Długosz-Danecka, Monika, additional, Silbermann, Rebecca, additional, Olszewski, Adam J., additional, Barth, Peter, additional, Mikala, Gabor, additional, Chim, Chor S., additional, and Vesole, David H., additional

Published
2020
Full Text
View/download PDF

4. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Author

Jurczyszyn, Artur, primary, Castillo, Jorge J., additional, Avivi, Irit, additional, Czepiel, Jacek, additional, Davila, Julio, additional, Vij, Ravi, additional, Fiala, Mark A., additional, Gozzetti, Alessandro, additional, Grząśko, Norbert, additional, Milunovic, Vibor, additional, Hus, Iwona, additional, Mądry, Krzysztof, additional, Waszczuk-Gajda, Anna, additional, Usnarska-Zubkiewicz, Lidia, additional, Dębski, Jakub, additional, Atilla, Erden, additional, Beksac, Meral, additional, Mele, Giuseppe, additional, Sawicki, Waldemar, additional, Jayabalan, David, additional, Charliński, Grzegorz, additional, Gyula Szabo, Agoston, additional, Hajek, Roman, additional, Delforge, Michel, additional, Kopacz, Agnieszka, additional, Fantl, Dorotea, additional, Waage, Anders, additional, Crusoe, Edvan, additional, Hungria, Vania, additional, Richardson, Paul, additional, Laubach, Jacob, additional, Guerrero-Garcia, Thomas, additional, Liu, Jieqi, additional, and Vesole, David H., additional

Published
2018
Full Text
View/download PDF

7. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

Author

Siegel, David S., primary, Weisel, Katja C., additional, Dimopoulos, Meletios A., additional, Baz, Rachid, additional, Richardson, Paul, additional, Delforge, Michel, additional, Song, Kevin W., additional, San Miguel, Jesus F., additional, Moreau, Philippe, additional, Goldschmidt, Hartmut, additional, Cavo, Michele, additional, Jagannath, Sundar, additional, Yu, Xin, additional, Hong, Kevin, additional, Sternas, Lars, additional, Zaki, Mohamed, additional, and Palumbo, Antonio, additional

Published
2016
Full Text
View/download PDF

8. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients

Author

Jurczyszyn, Artur, primary, Olszewska-Szopa, Magdalena, additional, Hungria, Vania, additional, Crusoe, Edvan, additional, Pika, Tomas, additional, Delforge, Michel, additional, Leleu, Xavier, additional, Rasche, Leo, additional, Nooka, Ajay K., additional, Druzd-Sitek, Agnieszka, additional, Walewski, Jan, additional, Davila, Julio, additional, Caers, Jo, additional, Maisnar, Vladimir, additional, Gertz, Morie, additional, Gentile, Massimo, additional, Fantl, Dorotea, additional, Mele, Giuseppe, additional, Vesole, David H., additional, Yee, Andrew J., additional, Shustik, Chaim, additional, Lentzsch, Suzanne, additional, Zweegman, Sonja, additional, Gozzetti, Alessandro, additional, Skotnicki, Aleksander B., additional, and Castillo, Jorge J., additional

Published
2016
Full Text
View/download PDF

9. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone.

Author

Vogl, Dan T., Delforge, Michel, Song, Kevin, Guo, Shien, Gibson, Craig J., Ervin-Haynes, Annette, and Facon, Thierry

Subjects
*QUALITY of life, *DEXAMETHASONE, *MULTIPLE myeloma, *B cell lymphoma, *CANCER patients
Abstract

The FIRST trial demonstrated that continuous therapy with lenalidomide and dexamethasone (Rd) prolongs overall survival (OS) and improves health-related quality of life (HRQoL) during the first 18 months of therapy in newly diagnosed multiple myeloma (NDMM) patients. However, patient-reported HRQoL data were not collected after 18 months. We therefore estimated HRQoL scores based on time-varying data collected during progression-free follow-up after 18 months. During the initial 18 months of Rd, observed changes from baseline were within the 95% confidence interval of the predictive models at 33 of 35 time points across 7 HRQoL scores. Predicted scores after 18 months of therapy showed that observed HRQoL improvements during therapy were maintained or improved. Therefore, the survival gain observed with Rd does not come at a cost of declining HRQoL during continuous therapy beyond 18 months, supporting long-term Rd as a standard of care for initial myeloma therapy. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

11. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial

Author

Dimopoulos, Meletios A., primary, Palumbo, Antonio, additional, Hajek, Roman, additional, Kropff, Martin, additional, Petrucci, Maria Teresa, additional, Lewis, Philip, additional, Millar, Stefanie, additional, Zhang, Jingshan, additional, Mei, Jay, additional, and Delforge, Michel, additional

Published
2013
Full Text
View/download PDF

13. Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multi-center phase II trial.

Author

Delforge, Michel, Devos, Timothy, Rowe, Jacob, Español, Ignacio, Durrant, Simon T., Raddoux, Jolien, Boogaerts, Marc, Gramatzki, Martin, and Gunther, Andreas

Subjects
*ZOLEDRONIC acid, *MYELOFIBROSIS, *DIPHOSPHONATES, *BONE resorption, *HYPERCALCEMIA, *OSTEOPOROSIS treatment, *PATIENTS, *THERAPEUTICS
Abstract

The article reports on lack of clinical benefit of zoledronic acid in myelofibrosis, a results of multi-center phase II trial. It states that bisphosphonates inhibitors of osteoclast mediated bone resorption and an established treatment for hypercalcemia of malignancy, osteoporosis and solid tumors. It mentions that zoledronic acid to provide benefit over treatment with the nitrogen-containing bisphosphonates (N-BPs) and has beneficial effect on blood counts became apparent after infusion.

Published
2016
Full Text
View/download PDF

15. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.

Author

Dimopoulos, Meletios A., Palumbo, Antonio, Hajek, Roman, Kropff, Martin, Petrucci, Maria Teresa, Lewis, Philip, Millar, Stefanie, Zhang, Jingshan, Mei, Jay, and Delforge, Michel

Subjects
MULTIPLE myeloma treatment, QUALITY of life measurement, MELPHALAN, PREDNISONE, IMMUNOLOGICAL adjuvants, COMBINATION drug therapy, RANDOMIZED controlled trials, THERAPEUTICS
Abstract

In the MM-015 trial, melphalan-prednisone-lenalidomide followed by lenalidomide maintenance (MPR-R) significantly prolonged progression-free survival versus melphalan-prednisone (MP) in newly diagnosed patients with multiple myeloma aged ≥ 65 years. Health-related quality of life (HRQoL), a secondary endpoint of MM-015, was also improved with MPR-R. This sub-analysis evaluated the impact of individual predictive factors on HRQoL. Patients completed HRQoL questionnaires at baseline, every third cycle and at progressive disease (PD)/treatment discontinuation. In a mixed-effects model female gender, advanced age and PD negatively affected HRQoL while better treatment responses showed positive effects. Compared to PD, HRQoL during MPR-R treatment was statistically significantly better in two of six preselected domains both of which were also clinically meaningful. HRQoL scores at end of treatment were all either improved or not statistically significantly different versus baseline. In conclusion, continuous treatment with MPR-R, which delays PD, appears to be associated with clinically meaningful improvements in HRQoL. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results